EUVIMEDEUVIMED entdecken
Crossref

Combined therapy with myo-inositol and D-chiro-inositol for metabolic and reproductive disorders: a clinical rationale

E.Yu. Volkova, S.A. Gasparyan

Lechaschi Vrach · 20.05.2026 · (5(29))

DOI: 10.51793/os.2026.29.5.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lechaschi Vrach, erschienen am 20.05.2026. Verfasst von E.Yu. Volkova und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Polycystic ovary syndrome, insulin resistance, and metabolic disorders are among the most common causes for reduced fertility in reproductive-aged women. Impaired insulin signaling leads to secondary hyperinsulinemia and hyperandrogenism, which contribute to anovulation, irregular menstrual cycles, and reduced fertility. Inositols have recently received considerable attention as physiological insulin sensitizers capable of restoring metabolic and endocrine homeostasis without the use of hormone therapy.

Objective

Present study aimed to substantiate the efficacy and safety of the use of the dietary supplement RitmoZhinel®, which contains myo-inositol and D-chiro-inositol in a physiological ratio of 40:1, as well as alpha-lipoic and folic acids, vitamins D3, B5, B6, C, E, chromium, and manganese.

Results

The analysis of clinical studies and literature data has demonstrated that inositols enhance tissue sensitivity to insulin, reduce androgen levels, restores ovulation and menstrual function. Meta-analyses demonstrate a statistically significant reduction in the HOMA-IR index, decreased testosterone levels, and increased ovulation frequency compared with the placebo group. Additional components of the agent provide antioxidant protection, maintain hormonal equilibrium, and potentiate the metabolic effects of inositols.

Conclusion

The body of evidence confirms the pathogenetically substantiated efficacy of a compound as a non-hormonal agent in supporting reproductive health in women with polycystic ovary syndrome and insulin resistance. Its favorable safety profile and good tolerability highlight the potential of this agent as a promising avenue for nutritional support of women’s metabolic and endocrine health.

Zitieren

APA

Volkova, E., & Gasparyan, S. (2026). Combined therapy with myo-inositol and D-chiro-inositol for metabolic and reproductive disorders: a clinical rationale. Lechaschi Vrach. https://doi.org/10.51793/os.2026.29.5.015

Vancouver

Volkova E, Gasparyan S. Combined therapy with myo-inositol and D-chiro-inositol for metabolic and reproductive disorders: a clinical rationale. Lechaschi Vrach. 2026. doi:10.51793/os.2026.29.5.015

BibTeX
@article{Volkova2026,
  author = {Volkova, E.Yu. and Gasparyan, S.A.},
  title = {Combined therapy with myo-inositol and D-chiro-inositol for metabolic and reproductive disorders: a clinical rationale},
  journal = {Lechaschi Vrach},
  year = {2026},
  number = {5(29)},
  doi = {10.51793/os.2026.29.5.015}
}
Kostenlos starten →